Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis.

Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S, Levy R, Williams W, Gottlieb A.

J Am Acad Dermatol. 2012 Oct;67(4):658-64. doi: 10.1016/j.jaad.2011.12.018. Epub 2012 Jan 24.

PMID:
22281165
2.

Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.

Punwani N, Burn T, Scherle P, Flores R, Shi J, Collier P, Hertel D, Haley P, Lo Y, Waeltz P, Rodgers J, Shepard S, Vaddi K, Yeleswaram S, Levy R, Williams W, Gottlieb AB.

Br J Dermatol. 2015 Oct;173(4):989-97. doi: 10.1111/bjd.13994. Epub 2015 Oct 14.

PMID:
26123031
3.

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

Fridman JS, Scherle PA, Collins R, Burn T, Neilan CL, Hertel D, Contel N, Haley P, Thomas B, Shi J, Collier P, Rodgers JD, Shepard S, Metcalf B, Hollis G, Newton RC, Yeleswaram S, Friedman SM, Vaddi K.

J Invest Dermatol. 2011 Sep;131(9):1838-44. doi: 10.1038/jid.2011.140. Epub 2011 Jun 16.

5.

Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.

Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, Brundage T, Wyres M; U0267-301 & 302 Study Investigators.

Am J Clin Dermatol. 2012 Aug 1;13(4):261-71. doi: 10.2165/11630710-000000000-00000. Erratum in: Am J Clin Dermatol. 2012 Dec 1;13(6):422.

PMID:
22587791
6.

A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.

Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, Berne B, Figueiredo A, Austad J.

J Am Acad Dermatol. 2008 Sep;59(3):455-63. doi: 10.1016/j.jaad.2008.04.027.

PMID:
18694678
8.

Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial.

White S, Vender R, Thaçi D, Haverkamp C, Naeyaert JM, Foster R, Martinez Escribano JA, Cambazard F, Bibby A.

Am J Clin Dermatol. 2006;7(3):177-84.

PMID:
16734505
10.

Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks.

Singh S, Reddy DC, Pandey SS.

J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):61-5.

PMID:
10863225
11.

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A.

N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.

12.

Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by different formulations of calcipotriol.

Cassano N, Miracapillo A, Coviello C, Loconsole F, Bellino M, Vena GA.

Clin Drug Investig. 2006;26(4):227-33.

PMID:
17163256
13.

Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.

McCormack PL.

Am J Clin Dermatol. 2011 Dec 1;12(6):421-4. doi: 10.2165/11207670-000000000-00000. Review.

PMID:
21967117
15.

Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).

Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Østerdal ML, Stein Gold L.

J Drugs Dermatol. 2015 Dec;14(12):1468-77.

PMID:
26659941
16.

Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.

Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J.

Pediatr Dermatol. 2015 Jan-Feb;32(1):28-35. doi: 10.1111/pde.12429. Epub 2014 Nov 21.

17.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S.

Blood. 2010 Apr 15;115(15):3109-17. doi: 10.1182/blood-2009-04-214957. Epub 2010 Feb 3.

18.

Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial.

Ortonne JP, Esposito M, Chimenti S, Kapińska-Mrowiecka M, Grodzińska A, Naldi L, Frangione V.

J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1226-34. doi: 10.1111/jdv.12270. Epub 2013 Oct 29.

19.

Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.

Menter A, Gold LS, Bukhalo M, Grekin S, Kempers S, Boyce BM, Ganslandt C, Villumsen J, Lebwohl M.

J Drugs Dermatol. 2013 Jan;12(1):92-8.

PMID:
23377334

Supplemental Content

Support Center